Conferences - Results from #140

ASCO GU 2021: Efficacy of Cabozantinib in Advanced MiT Family Translocation Renal Cell Carcinomas February 14, 2021

ASCO GU 2021: Sunitinib Versus Cabozantinib, Crizotinib or Savolitinib in Metastatic Papillary Renal Cell Carcinoma (pRCC): Results from the Randomized Phase II SWOG 1500 Study February 13, 2021

ASCO GU 2021: Outcomes For Patients In the Pembrolizumab+Axitinib Arm With Advanced Renal Cell Carcinoma Who Completed Two Years Of Treatment In The Phase III KEYNOTE-426 Study February 13, 2021

ASCO GU 2021: Patient-Reported Outcomes Of Patients With Advanced Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Cabozantinib Versus Sunitinib: The Checkmate 9ER Trial February 13, 2021

ASCO GU 2021: Nivolumab + Cabozantinib Versus Sunitinib for Advanced Renal Cell Carcinoma (aRCC): Outcomes by Sarcomatoid Histology and Updated Trial Results with Extended Follow-up of CheckMate 9ER February 13, 2021

ASCO GU 2021: Efficacy and Safety of Avelumab plus Axitinib (A + Ax) Versus Sunitinib (S) in Elderly Patients with Advanced Renal Cell Carcinoma (aRCC): Extended Follow-up Results from JAVELIN Renal 101 February 13, 2021

ASCO GU 2021: Phase 2 Study of the Oral Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma February 13, 2021

ASCO GU 2021: Bench to Bedside: Critical Pathways in Renal Cell Carcinoma – Pathways to Detection February 13, 2021

ASCO GU 2021: Bench to Bedside: Critical Pathways in Renal Cell Carcinoma – Pathways to RCC Inception February 13, 2021

ASCO GU 2021: The Potential Role of Frailty in Modifying Quality-of-Life Related Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Docetaxel, Abiraterone, Enzalutamide, and Radium 223 February 13, 2021

ASCO GU 2021: Bench to Bedside: Critical Pathways in Renal Cell Carcinoma - Pathways to Metastatic Colonization in Kidney Cancer February 13, 2021

ASCO GU 2021: Therapy-Relevant Gene Signatures In The High Risk Localized Renal Cell Carcinoma Setting: Transcriptomic Data From Patients Receiving Placebo On A Randomized Phase III Trial (PROTECT) February 13, 2021

ASCO GU 2021: Gene Expression Profiling to Identify Metabolic Gene Signature Predictive of Recurrence After Surgery In Stage III Clear-Cell RCC February 13, 2021

ASCO GU 2021: Real-World Treatment Patterns and Sequencing for mRCC: Results from the Flatiron Database February 13, 2021

ASCO GU 2021: Safety and Efficacy of Nivolumab in Older Patients with Renal Cell Carcinoma: Results of a Sub-Group Analysis of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study February 13, 2021

ASCO GU 2021: Phase II Trial of Lenvatinib at Two Starting Doses plus Everolimus in Patients with RCC: Results by Independent Imaging Review and Prior Immune Checkpoint Inhibition February 13, 2021

ASCO GU 2021: Nivolumab plus Ipilimumab in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma (nccRCC): Safety and Efficacy from CheckMate 920 February 13, 2021

ASCO GU 2021: Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-Resistant Prostate Cancer February 13, 2021

ASCO GU 2021: Dose-intensification among Patients Receiving Salvage RT Following Radical Prostatectomy and the Clinical Cell-cycle Risk Score to Identify Men Who Can Forgo ADT at the Time of Dose-Escalated RT for Prostate Cancer - Discussion February 13, 2021

ASCO GU 2021: Association Between Tumor Mutational Burden and Immune-Related Adverse Events in Patients with Metastatic Urothelial Carcinoma During Checkpoint Immunotherapy February 13, 2021

Page 8 of 392